Sun Pharmaceutical Industries Limited v. Systopic Laboratories Limited

13800732

The Delhi High Court allowed Sun Pharmaceutical Industries Limited to frame a new issue in its ongoing suit against Systopic Laboratories Limited. The core dispute involves the similarity between the trademarks 'STORVAS' and 'ORVAS'. Crucially, the court permitted the framing of an additional issue questioning the validity and potential cancellation of the defendant's trademark registration (No. 1328403). This decision was influenced by recent Supreme Court dicta emphasizing the necessity of addressing pleas of invalidity.

Jurisdiction
India
Court / Office
Delhi High Court
Case Number
13800732
Judge(s)
Rajiv Sahai Endlaw

Detailed Summary

In the fiercely competitive pharmaceutical industry, a brand name is often a company's most valuable asset. But what happens when two drug brands sound so similar that confusion seems inevitable? The Delhi High Court recently faced this exact question in a battle between two pharma players, and the court's decision to allow a new line of attack could change how trademark wars are fought in India. This case is a masterclass in how procedural strategy can unlock powerful legal remedies.

Sun Pharmaceutical Industries Limited, one of India's largest pharmaceutical companies, found itself in a trademark dispute with Systopic Laboratories Limited. At the heart of the conflict were two competing drug brands: Sun Pharma's 'STORVAS' and Systopic's 'ORVAS'. The phonetic and visual similarity between the two marks raised serious concerns about potential market confusion. The dispute had already progressed into a formal suit, but as the case moved forward, Sun Pharma sought to introduce a new legal dimension, one that went beyond simply proving similarity.

Sun Pharma's argument was strategic and forward-looking. Rather than relying solely on the argument that 'STORVAS' and 'ORVAS' were confusingly similar, Sun Pharma pushed to frame an additional issue: the validity of Systopic's trademark registration itself. Specifically, Sun Pharma sought to challenge Trademark Registration No. 1328403 held by Systopic, arguing that this registration should be scrutinized for potential cancellation. The legal friction here was significant. By attacking the validity of the registered trademark, Sun Pharma was attempting to strip away the very foundation of Systopic's brand protection. This move aligned with recent Supreme Court observations that emphasized the necessity of properly addressing pleas of invalidity in trademark suits, rather than leaving them unexamined.

The Delhi High Court ruled in favor of allowing Sun Pharma to frame this new issue. The court recognized that the plea regarding the invalidity of Systopic's trademark registration was a material question that deserved formal consideration within the suit. Influenced by the Supreme Court's recent dicta on the importance of addressing invalidity pleas, the court permitted the additional issue to be framed. This was a significant procedural win for Sun Pharma, as it opened the door to potentially having Systopic's registration cancelled entirely, not just limited in scope. The outcome was mixed in the broader sense: while Sun Pharma secured this important procedural victory, the underlying trademark dispute between 'STORVAS' and 'ORVAS' remained ongoing.

For founders and IP professionals, this case delivers a critical lesson: do not underestimate the power of procedural framing. If you believe a competitor's trademark registration is weak or invalid, raising that plea clearly in your pleadings, supported by substantive arguments, can be enough to convince a court to formally frame an issue around it. You do not always need an explicit declaration from the court that your plea has merit; the very act of framing a material issue on invalidity can itself signal prima facie merit. In IP battles, attacking the foundation of a competitor's registration can be just as powerful as arguing similarity, and sometimes, it is the smarter strategic move.

Practitioner Note

This case demonstrates the evidentiary and procedural standards applied in patent matters before Delhi High Court. Understanding the court's reasoning in Sun Pharmaceutical Industries Limited vs Systopic Laboratories Limited is valuable context for structuring arguments or assessing risk in similar proceedings.

Related Cases

patentCMA(PT) No. 22 of 2025

The North Face Apparel CorpvsController of Patents and Designs

The North Face Apparel Corp challenged the Controller of Patents' refusal of its patent application (No. 202147026139) titled 'Systems and Methods for End-to-End Article Management' before the Madras High Court under Section 117A of the Patents Act, 1970. The Controller had rejected the application citing lack of inventive step over prior art documents D21-D24. The Court held that the Controller erred by dissecting the claims into isolated elements rather than assessing the invention as a whole, and overlooked the use of spectrophotometer and invisible markers for tracking the manufacturing process, which were not disclosed in the cited prior art. The appeal was allowed and the Controller was directed to grant the patent.

patentCMA(PT) No. 62 of 2024

Aventose Energy Private LimitedvsThe Assistant Controller of Patents & Designs, Patent Office Chennai

Aventose Energy Private Limited appealed under Section 117A of the Patents Act, 1970 against the refusal of its patent application (No. 202141019671) for a 'System and Method for Operating Automobiles with an Electric Drivetrain' featuring safe mode activation upon fault detection. The Madras High Court found that the Assistant Controller had contradicted the First Examination Report (which accepted novelty) by subsequently holding the invention lacked novelty without giving the applicant an opportunity to be heard. The court further held that the Controller improperly conflated novelty with inventive step under Section 2(1)(ja) and failed to properly analyze the claims against prior art documents D1–D4.

patentOA Nos. 1108, 1109 & 1110 of 2026 in C.S(COMM DIV) No. 279 of 2026

Apex Laboratories Pvt LtdvsElder Lifescience and Ambico Ayurvedic Health Care

Apex Laboratories Pvt Ltd, the prior adopter and registered proprietor of the trademark ZINCOVIT (TM No. 487453 in Class 5) since 1988, sought interim injunction against Elder Lifescience and Ambico Ayurvedic Health Care for using the deceptively similar mark NEO ZINCOVIT. The applicant also claimed copyright infringement of its registered artistic works (A-108878/2014) covering colour scheme, get-up, and layout. The Madras High Court was satisfied that the respondents were attempting to piggyback on the applicant's goodwill and granted interim injunctions on all three applications covering trademark infringement, copyright infringement, and passing off.

patent

Radico Khaitan LimitedvsPicadilly Agro Industries Limited

This Special Leave Petition arose from a judgment dated 29-05-2026 in CS No. 8/2025 passed by the District Judge, Karnal, Haryana, concerning a trademark dispute over the marks 'Cashmere' and 'Kashmyr' used in relation to beer and vodka. The Supreme Court noted that a First Appeal (FAO-COM-11-2026) was already pending before the Division Bench of the Punjab and Haryana High Court, listed for 28.10.2026. The Court disposed of the SLP without adjudicating it on merits, requesting the High Court to pass an appropriate order regarding the ad interim injunction on the scheduled date.

patent

Maharaja Agrasen Technical Educational Society (Regd.)vsMaharaja Agrasen Himalayan Garhwal University

The plaintiff, Maharaja Agrasen Technical Educational Society, filed a suit for permanent injunction against the defendant, Maharaja Agrasen Himalayan Garhwal University, alleging infringement and passing off regarding the use of the words 'Maharaja Agrasen' in the defendant's name. The Delhi High Court had previously granted a restraint order on 10.07.2026. During the pendency of the suit, the parties arrived at a settlement dated 14.09.2026, under which the defendant agreed to change its name through a statutory amendment while being permitted limited transitional use of its existing name. The court recorded the settlement, modified the interim order accordingly, and listed the matter for compliance reporting on 13.07.2027.

patent

Varahi Diamonds And Finance LimitedvsSahil Vinay Mehra Trading As Mehra Sons Jewellers & Anr.

This is a commercial suit filed by Varahi Diamonds And Finance Limited against Sahil Vinay Mehra Trading As Mehra Sons Jewellers & Anr. before the Delhi High Court. The order is primarily procedural, dealing with the registration of the plaint, issuance of summons, directions for filing pleadings, and an interim injunction application. The matter was referred to mediation, with parties directed to appear before the Delhi High Court Mediation and Conciliation Centre.

Arctic Invent — IP Strategy

Dealing with a patent challenge?

Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.

Talk to our patent team →

Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.

Strategy Consult

Facing a similar patent matter?

Arctic's litigation team uses precedent data like this to build winning arguments.

Get a Strategy Call